Janssen oversaw a mid-stage trial of 110 evaluable patients whose focal onset seizures had not been adequately controlled by the approved epilepsy meds levetiracetam or brivaracetam. (BSR Agency/Getty ...
Hosted on MSN
Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Bright Minds Biosciences Inc. is one of them. Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a biotechnology company ...
Rapport Therapeutics, a young biotech company with technology from the labs of Johnson & Johnson, is now preparing to enter the public markets to finance clinical research for a lead program that ...
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results